Additionally, researchers revealed that cancer-associated fibroblasts (CAFs) from osimertinib-resistant lung adenocarcinoma (LUAD) tissues produce higher levels of colony-stimulating factor 2 (CSF2) compared to those from osimertinib-sensitive tissues. This evidence concerns the gene CSF2 and cancer.